ICPT Intercept Pharmaceuticals, Inc.

-2.27  -2%
Previous Close 117.53
Open 117.98
Price To book 12.24
Market Cap 2.88B
Shares 25,009,000
Volume 228,905
Short Ratio 11.51
Av. Daily Volume 350,189

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due mid-2017. Phase 3 trial to be initiated 2H 2017.
Obeticholic acid (OCA) - CONTROL
NASH patients taking statins
Approved May 27 2016.
Obeticholic acid (OCA)
Primary biliary cirrhosis (PBC) - POISE
Phase 3 data due 1H 2019.
Obeticholic acid (OCA) - REGENERATE
Adult nonalcoholic steatohepatitis (NASH) patients.
Phase 2 data due mid-2017.
Obeticholic acid (OCA) AESOP
Primary Sclerosing Cholangitis (PSC)

Latest News

  1. Health Canada Grants Approval for Ocaliva™ (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis (PBC)
  2. Intercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva® (obeticholic acid)
  3. Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : May 18, 2017
  4. Intercept to Present at Upcoming Conferences
  5. ETFs with exposure to Intercept Pharmaceuticals, Inc. : May 15, 2017
  6. Intercept Pharmaceuticals, Inc. :ICPT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  7. Edited Transcript of ICPT earnings conference call or presentation 4-May-17 12:30pm GMT
  8. Another top executive at ​Sanofi Genzyme leaves company
  9. Intercept Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ICPT) : May 8, 2017
  10. These Biotechs Are Grabbing Bullish Views In Wake Of Earnings
  11. Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat
  12. Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : May 5, 2017
  13. Intercept (ICPT) Reports A Narrower Loss in Q1
  14. Intercept reports 1Q loss
  15. Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
  16. Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More
  17. Is Intercept (ICPT) Poised for a Beat This Earnings Season?
  18. Intercept to Report First Quarter 2017 Financial Results on May 4 and Present at Upcoming Conference
  19. Should Gilead Sciences Be Worried About Allergan?
  20. Intercept Announces New Ocaliva® (obeticholic acid) and INT-767 Data to be Presented at EASL 2017